| Prevention | |
| Aggressive multiagent therapy | |
| Appreciation of factors that induce resistance mechanisms | |
| Circumvention: drug screening programs and rational drug design | |
| Circumvention of drug-uptake defects | |
| Dose escalation | |
| Drugs that use alternate transport mechanisms | |
| Agents that reverse increased efflux | |
| Co-factors that augment drug activation or efficacy | |
| Inhibition of drug inactivation | |
| Novel treatment modalities | |
| Immunotherapy | |
| Development of agents that target signaling and apoptotic pathways | |
From: Overview of Resistance to Systemic Therapy in Patients with Breast Cancer
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.